Table 6 Univariate and multivariate analysis of factors predicting LRR in patients undergoing mastectomy after NAC

Age (years)

0.477

≦50

30 (9.8%)

275 (90.2%)

 > 50

36 (11.6%)

274 (88.4%)

Clinical T stage

0.019

 T1

3 (20.0%)

12 (80.0%)

1

 T2

23 (9.1%)

229 (90.9%)

0.335

0.081–1.380

0.13

 T3

9 (6.1%)

138 (93.9%)

0.228

0.050–1.035

0.055

 T4

31 (15.4%)

170 (84.6%)

0.434

0.105–1.782

0.246

Clinical lymph node status

 < 0.001

 N0

1 (4.8%)

20 (95.2%)

1

 N1

16 (5.7%)

264 (94.3%)

1.223

0.151–9.914

0.85

 N2

49 (15.6%)

265 (84.4%)

2.983

0.380–23.421

0.299

SBR grade

0.07

 1

1 (2.1%)

46 (97.9%)

 2

25 (10.3%)

217 (89.7%)

 3

37 (13.5%)

238 (86.5%)

 Unknown

3 (5.9%)

48 (94.1%)

Histologic type

0.534

 Invasive ductal carcinoma

64 (10.6%)

539 (89.4%)

 Invasive lobular carcinoma

1 (16.7%)

5 (83.3%)

 Mucinous carcinoma

0

3 (100.0%)

 Others

1 (33.3%)

2 (66.7%)

Margin

 > 0.999

 Free

66 (10.1%)

541 (89.1%)

 Positive

0

8 (100.0%)

ER

0.032

 Positive

33 (8.6%)

349 (91.4%)

1

 Negative

33 (14.2%)

200 (85.8%)

1.837

1.078–3.131

0.025

PR

0.105

 Positive

29 (8.8%)

299 (91.2%)

 Negative

37 (12.9%)

250 (87.1%)

HER2

0.51

 Positive

27 (9.8%)

248 (90.2%)

 Negative

39 (11.5%)

301 (88.5%)

Subtype

0.206

 HR + /HER2−

26 (9.8%)

240 (90.2%)

 HR + /HER2 + 

11 (8.5%)

119 (91.5%)

 HR−/HER2 + 

16 (11.0%)

129 (89.0%)

 HR−/HER2−

13 (17.6%)

61 (82.4%)

Neoadjuvant regimens

0.229

 Anthracycline only

5 (19.2%)

21 (80.8%)

 Taxane only

5 (11.4%)

39 (88.6%)

 Anthracycline + Taxane

44 (11.6%)

336 (88.4%)

 Chemotherapy + Target therapy

12 (7.3%)

153 (92.7%)

pCR

0.034

 Yes

4 (4.4%)

87 (95.6%)

1

 No

62 (11.8%)

462 (88.2%)

2.524

0.856–7.444

0.093